Ticker LaunchUplisting · SILO
Silo Pharma, Inc.
Formerly Uppercut Brands, Inc.; Point Capital, Inc.; Gold Swap Inc
Silo Pharma, Inc. (SILO), already reporting to the SEC, moved up to Nasdaq Capital Market on Sep 28, 2022 with an offering at $5.00 per share. Laidlaw was lead-left underwriter. Sheppard Mullin advised the company and Sichenzia Ross Ference Carmel advised the underwriters.
Silo Pharma, Inc. is a developmental stage biopharmaceutical company combining traditional therapeutics with psychedelic research. It seeks to acquire or develop technology rights from universities and researchers to treat rare diseases and mental health and neurological conditions, including with psilocybin.
- Status
- Uplisting
- Ticker
- SILO
- Exchange
- Nasdaq Capital Market
- Listed
- Sep 28, 2022
- Price
- $5.00
- Market cap at IPO price
- $14.9M
- First filed
- Mar 30, 2011
- Underwriters
- Laidlaw
- Company counsel
- Sheppard Mullin
- Underwriters' counsel
- Sichenzia Ross Ference Carmel
- Sector
- Biotech & pharma
- Country / state
- FL
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Mar 30, 2011
- Latest amendment Sep 20, 2022
- Final prospectus (424B4) Sep 28, 2022
- All filings on EDGAR CIK 1514183
Other Biotech & pharma uplistings in 2022
- Sunshine Biopharma Inc.SBFM · Feb 17, 2022 · $8M